Navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study (original) (raw)

Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis

Sanjay Akhani

Future Oncology

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis

Haematologica, 2016

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis

Timothy Devos

Journal of Clinical Oncology

Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis

Clinical Cancer Research, 2012

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012

Mary McMullin

British Journal of Haematology, 2014

Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis

kate burbury

Blood, 2020

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial

Anita Szőke

JAMA oncology, 2018

Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients

Daniel El Fassi

Blood, 2020

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Journal of hematology & oncology, 2017

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

Jordan Fridman

New England Journal of Medicine, 2010

Beyond JAK2 Inhibitors: A Systematic Review of Management Strategies for Myelofibrosis

yasemin dede

Blood, 2018

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

Joy Zhu

Blood, 2015

Clinical and molecular correlates of JAK-inhibitor therapy failure in myelofibrosis: long-term data from a molecularly annotated cohort

Hassan Sibai

Leukemia

Development of ruxolitinib as a myelofibrosis therapy

Abdulkareem Almomen

Next Generation Therapeutics for the Treatment of Myelofibrosis

Cells, 2021

Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis

Lewis Silverman

Leukemia & Lymphoma, 2019

Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors

sylvia fagbemi

Journal of the Advanced Practitioner in Oncology, 2015

Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I

Blood, 2012

BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis

Dariusz Woszczyk

Future Oncology

Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis

Francesco Mendicino

Future oncology (London, England), 2015

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis

Nicholas Sarlis

Haematologica, 2015

‘JAK–ing’ up the treatment of primary myelofibrosis

Rita Assi

Current Opinion in Hematology, 2017

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

Alessandro Vannucchi

Journal of hematology & oncology, 2017

The Impact of Jak1/Jak2 Inhibitor Ruxolitinib on the Spleen Size and Symptom Burden in Myeloproliferative Diseases

sezgin etgül

International Journal of Hematology and Oncology, 2016

Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study

Pilar Giraldo

Hematological Oncology, 2021

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

Haematologica, 2015

Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly

Ohad Benjamini

Blood, 2012

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

Aref Al-kali

Leukemia, 2013

Looking forward: novel therapeutic approaches in chronic and advanced phases of myelofibrosis

Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2015

Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib

Ramy Abdelrahman

Leukemia, 2014

The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis

British Journal of Haematology, 2013

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib

J Mariano Anto Bruno Mascarenhas

Current Medicinal Chemistry, 2012

Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study

Catherine Bouard

Leukemia & Lymphoma, 2020

Ruxolitinib in the treatment of patients with myelofibrosis — questions and answers

Marta Sobas

Oncology in Clinical Practice